Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 17/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 14/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | PRKACB | P22694 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359480 | 0.89 | KDM4E (0.51) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359530 | 0.88 | XDH (0.51) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359390 | 0.88 | MIF (0.51) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359432 | 0.87 | PTPN11 (0.47) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359482 | 0.86 | XDH (0.51) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359485 | 0.86 | MIF (0.51) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359555 | 0.83 | PLAU (0.51) | KDM4EPOLBROCK2ROCK1PRKACA | |
| SCHEMBL21359523 | 0.82 | MIF (0.66) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL21359470 | 0.82 | XDH (0.48) | KDM4EPOLBROCK2ROCK1 | |
| SCHEMBL22861324 | 0.81 | ROCK2 (0.47) | KDM4EROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999723-B2 | Pyrazole-containing macrophage migration inhibitory factor inhibitors | YALE UNIVERSITY (US) | 2024-06-04 | — | — | US | disclosed |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2023-02-23 | — | — | US | disclosed |
| US-11465991-B2 | Pyrazole-containing macrophage migration inhibitory factor inhibitors | YALE UNIVERSITY (US) | 2022-10-11 | — | — | US | disclosed |
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2021-01-07 | — | — | US | disclosed |
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | UNIV YALE (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2019178480-A1 | PYRAZOLE-CONTAINING MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS | YALE UNIVERSITY (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999723-B2 | Pyrazole-containing macrophage migration inhibitory factor inhibitors | MIF, MMP12, CSF1R | KDM4E 1525/4885POLB 4781/4885ROCK2 1259/4885 |
| US-11465991-B2 | Pyrazole-containing macrophage migration inhibitory factor inhibitors | MIF, MMP12, CSF1R | KDM4E 1211/4885POLB 4740/4885ROCK2 1167/4885 |
| US-20210002264-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | KDM4E 1211/4885POLB 4740/4885ROCK2 1167/4885 |
| US-20230057076-A1 | Pyrazole-Containing Macrophage Migration Inhibitory Factor Inhibitors | MIF, MMP12, CSF1R | KDM4E 1525/4885POLB 4781/4885ROCK2 1259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.